Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. It blocks viral entry into host cells while preserving normal immunologic function. The Company is also investigating an intramuscular method of administration of Trogarzo. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy.


TSX:TH - Post by User

Comment by scarlet1967on Jun 26, 2022 8:22pm
96 Views
Post# 34783541

RE:RE:RE:RE:RE:RE:RE:Excess of adipose visceral fat causing NAFLD regardless of..

RE:RE:RE:RE:RE:RE:RE:Excess of adipose visceral fat causing NAFLD regardless of..

“EGRIFTA SV® is not approved to reduce the health consequences of excess visceral abdominal fat.

Medicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet. Do not use EGRIFTA SVTM for a condition for which it was not prescribed.”

 

https://www.egriftasv.com/pdf/EGRIFTA_SV_DiscussionGuide_FINAL.pdf

I have seen these GH deficiency clinics advertising about Tesamorelin just not sure how legit they are or where they get their inventory from?



jeffm34 wrote:

It can be prescribed right now to any patient with HIV lipodystrophy. Makes no difference if one the benefits of reducing abdominal fat is lower risk of NAFLD/NASH. It can even be prescribed off label if a physician sees a benefit. 

https://www.hgh.tv/tesamorelin-boosts-hgh-levels-and-burns-belly-fat

"Furthermore, Tesamorelin can be prescribed off-label, giving specialists at HRT Clinics more leeway to prescribe the treatment to patients that may be considered borderline HGH Deficiency or may otherwise benefit from enhanced HGH Production."


 

scarlet1967 wrote: Egrifta is not approved for any condition but HIV lipodystrophy yet! although there are many conditions related to viscera adiposity including NAFLD/NASH doctors can't prescribe the drug. If and when the drug gets approved for NASH I believe it is fairly easy to motivate the patients with a late stage liver disease to take the drug which should be easier to administer once they have the F8 approved as compared to SV the new formulation is much more concentrated thus less to be injected and also the multi dose pen injector will make the process more convenient.
 

 

PWIB123 wrote: Makes sense.  So at what point does someting like Egrifta become a measure a doctor would recommend?  I'm assuming this is easiest to recommend for HIV patients, because they already could benefit for other reasons in addition to NAFLD/NASH.  For general Nash population, however, what's the point where a doctor says you need to just give in and start taking a drug that's fairly complex to administer?

 




<< Previous
Bullboard Posts
Next >>

USER FEEDBACK SURVEY ×

Be the voice that helps shape the content on site!

At Stockhouse, we’re committed to delivering content that matters to you. Your insights are key in shaping our strategy. Take a few minutes to share your feedback and help influence what you see on our site!

The Market Online in partnership with Stockhouse